- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Exploring Screening and Real-World Use of Teplizumab: Practical Insights and Clinical Experiences
Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.
EP: 1.Navigating T1D: Mitigating Burden and Monitoring Disease Progression
EP: 2.T1D Staging: The Clinical Importance of Early Recognition
EP: 3.Engaging the Audience: Polling on Primary Populations and Community Perspectives in T1D Care
EP: 4.T1D Antibody Screening: Identifying High-Risk Populations
EP: 5.Role of Teplizumab: First Approved Treatment for Delaying T1D Stage Progression
EP: 6.TN-10 Study Analysis: Expert Perspectives on Key Efficacy and Safety Data
EP: 7.Exploring Screening and Real-World Use of Teplizumab: Practical Insights and Clinical Experiences
EP: 8.Teplizumab Infusion Protocol: Details on the 14-Day Process and Comprehensive Monitoring Overview
EP: 9.Expert Opinions into the Range of Teplizumab Infusion Locations, Insurance Coverage Hurdles, and the Approval Process
EP: 10.Final Thoughts on Strategies for Managing and Monitoring Patients Receiving Teplizumab
The following is a summary of the video transcript and has been edited for length and clarity.
Goldman: In terms of where infusions are being done, where are you sending your patients?
Shenkman: Right now, we're using a couple of local infusion centers. We are also exploring other options, like either home health or partial home health, where the patient starts treatment in an infusion center for the first few days to be monitored, and then the remainder is done through home health. A lot depends on whether there is space available 14 days in a row.
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
October 27th 2025After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
